LIVE MARKET TRACKER :   BSE SENSEX   33340.88      |    NSE NIFTY 10279.75    
GLOBAL MARKETS :  NASDAQ      |    FSI London      |    NIKKEI Japan  
  USD GBP EUR CAD AUD INR
USD -
GBP -
EUR -
CAD -
AUD -
INR -
Indian-Commodity  :  Top News  :  Cipla in partnership with MMV launches quality-assured RAS

Cipla in partnership with MMV launches quality-assured RAS (26-Jul-2017)

Cipla, a global pharmaceutical company, and the product development partnership Medicines for Malaria Venture (MMV) has launched 100 mg Artesunate Rectocaps/Rectal Artesunate Suppositories (RAS), a life-saving, pre-referral intervention for the management of severe malaria in young children.

Cipla's RAS product contains 100 mg of Artesunate and is indicated in children from 6 months to 6 years. It was developed with the support of MMV (with UNITAID financing) and will now soon be available in four sub-Saharan countries.

Initially developed by the World Health Organization's (WHO) Tropical Diseases Research programme, RAS 100 mg manufactured by Cipla was recently added to the Global Fund Expert Review Panel's list of quality-assured medicines, while the process of WHO prequalification of this medicine moves through its final stages. This authorization makes it the first quality-assured RAS product.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For 80 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 100 countries.




Top News Today
Escorts to increase product offering in construction equipment space: Report
(13-Dec-2017)

Escorts to increase product offering in construction equipment space: ReportEscorts is reportedly planning to increase product offering in the construction equipment space. The company is planning to do the same through joint ventures and technical collaborations besides in-house......click on news to read complete article.

Societe Generale buys 13 lakh shares of Bharat Financial Inclusion
(13-Dec-2017)

Societe Generale buys 13 lakh shares of Bharat Financial InclusionSociete Generale has bought 13,00,000 shares of Bharat Financial Inclusion for a total amount of Rs 129.04 crore. It has purchased the shares at Rs 992.65 per share on BSE on December 12, 2017. However,......click on news to read complete article.

FTAs witnesses a sharp jump of 14.4% in the month of November
(13-Dec-2017)

FTAs witnesses a sharp jump of 14.4% in the month of NovemberThe number of foreign tourist arrivals (FTAs) in India in the month of November witnessed a sharp jump of 14.4 per cent over the same period last year. As per the tourism ministry data, the number......click on news to read complete article.

International Stock News
US markets closed higher on Monday
(12-Dec-2017)

US markets closed higher on MondayThe US markets closed higher on Monday, with the S&P 500 index and Dow industrials closing at records on the back of a rally in telecommunications and technology shares. Wall Street shrugged off......click on news to read complete article.

Asian markets trade higher in early deals on Monday
(11-Dec-2017)

Asian markets trade higher in early deals on MondayAsian equity benchmark indices are trading higher in the early deals on Monday, lifted by encouraging employment data from the US that took the Standard & Poor's 500 Index to its third straight......click on news to read complete article.

US markets end at record highs on upbeat jobs data
(09-Dec-2017)

US markets end at record highs on upbeat jobs dataThe US markets traded with traction and ended near record high levels on Friday, as traders reacted positively to the closely watched monthly jobs report. The continued advance by stocks came following......click on news to read complete article.

 

     
  
Recent Top News News
 
EquityInvestmentCompany ReportsIPO
Disclaimer
By clicking on this page you accept all the terms and conditions framed by us. News made available here are for informational purpose only. While utmost care has been taken in providing the same. We claim no responsibility for its accuracy. Readers of this blog who make their decision based on the information posted here are solely responsible for their actions.